Menu Search
Equities

Novozymes A/S

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NSIS B:CPH

Novozymes A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)379.80
  • Today's Change2.80 / 0.74%
  • Shares traded161.92k
  • 1 Year change-13.09%
  • Beta0.6009
Data delayed at least 15 minutes, as of May 13 2026 15:07 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 15-May-25
  • 19-Feb-26
  • 19-Mar-26
  • 16-Apr-26
  • 13-May-26
Select bar for recommendation details.
Recommendations13-May-26
Buy5
Outperform13
Hold1
Sell0
Strong Sell0

Share price forecast in EUR

The 16 analysts offering 12 month price targets for Novozymes A/S have a median target of 469.90, with a high estimate of 560.29 and a low estimate of 380.25. The median estimate represents a 24.64% increase from the last price of 377.00.
High48.6%560.29
Med24.6%469.90
Low0.9%380.25

Dividends in EUR

In 2025, Novozymes A/S reported a dividend of 0.87 EUR, which represents a 4.67% increase over last year. The 15 analysts covering the company expect dividends of 0.93 EUR for the upcoming fiscal year, an increase of 7.31%.
Note: The percentage change is calculated using unrounded (raw) dividend values.
Div growth (TTM)4.67%
More ▼

Earnings history & estimates in EUR

On May 05, 2026, Novozymes A/S reported 1st quarter 2026 earnings of 0.44 per share.
The next earnings announcement is expected on Aug 20, 2026.
Average growth rate-3.83%
Novozymes A/S reported annual 2025 earnings of 1.49 per share on Feb 25, 2026.
Average growth rate+1.09%
More ▼

Revenue history & estimates in EUR

Novozymes A/S had 1st quarter 2026 revenues of 1.12bn. This bettered the 1.11bn consensus of the 3 analysts covering the company. This was 3.87% above the prior year's 1st quarter results.
Average growth rate+1.24%
Novozymes A/S had revenues for the full year 2025 of 4.16bn. This was 5.38% above the prior year's results.
Average growth rate+22.19%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.